Document Detail


Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression.
MedLine Citation:
PMID:  1377118     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) is a polypeptide hormone produced through recombinant DNA technologies in glycosylated (yeast or mammalian expression systems) or nonglycosylated (Escherichia coli expression system) form. It is a multilineage haematopoietin which stimulates proliferation and differentiation of bone marrow myeloid progenitors and increases peripheral white blood cell counts when administered systemically. Treatment is generally well tolerated, although mild to moderate flu-like symptoms are common and rGM-CSF-induced fever and fluid retention may be problematic in occasional patients. rGM-CSF accelerates recovery of peripheral neutrophil counts after bone marrow transplantation, and results of a placebo-controlled randomised trial correlate this with reduced infectious episodes and shortened length of hospitalisation in patients with lymphoid malignancies. A substantial number of patients with graft failure after bone marrow transplantation also respond to rGM-CSF. The duration of myelosuppression secondary to cancer chemotherapy can be significantly reduced by rGM-CSF which has permitted investigation of antineoplastic dose-intensity escalation. In some haematopoietic disorders (e.g. aplastic anaemia, myelodysplasia and neutropenia secondary to HIV infection and antiviral therapy), rGM-CSF produces clinically useful increases in peripheral blood granulocyte counts, although the effect is generally not sustained after drug withdrawal. The potential for rGM-CSF to stimulate proliferation of the abnormal clone in myelodysplasia and in acute myelogenous leukaemia following induction therapy is of concern. Available data suggest, however, that with appropriate monitoring and exclusion of high-risk patients this serious potential risk can be avoided, and that myelopoiesis is enhanced in such patients by rGM-CSF treatment. Recombinant colony-stimulating factors are a new therapeutic modality; hence many aspects of their use remain to be clarified. Nonetheless, as one of a small group of novel agents rGM-CSF has major potential in the management of myelosuppression secondary to cytoreductive therapy with or without bone marrow transplantation, and in amelioration of disturbed myelopoiesis. It represents an important application of biotechnology to a difficult area of therapeutics.
Authors:
S M Grant; R C Heel
Related Documents :
9881428 - Transfusion-related acute lung injury (trali) following autologous stem cell transplant...
2697588 - Autologous bone marrow transplantation therapy for multiple myeloma.
8640158 - Hematopoietic precursor cell transplants in europe: activity in 1994. report from the e...
14684148 - The therapy of relapsed acute leukaemia in adults.
15516258 - Campath and renal transplant rejection.
3091928 - Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubul...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  43     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1992 Apr 
Date Detail:
Created Date:  1992-07-30     Completed Date:  1992-07-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  516-60     Citation Subset:  IM    
Affiliation:
Adis International Limited, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bone Marrow Diseases / drug therapy
Bone Marrow Transplantation
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology*,  therapeutic use
Humans
Recombinant Proteins / adverse effects,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 83869-56-1/Granulocyte-Macrophage Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of sedative agents in critically ill patients.
Next Document:  Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness.